Splice modulating oligomers as cancer therapeutics
Authors:
- KuanHui E. ChenKCKuanHui E. Chen
- Ameae M. WalkerAmeae M. Walker
Open Access
- 26 August 2022
- journal article
- editorial
- Published by Impact Journals, LLC in Genes & Cancer
- Vol. 13, 46-48
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Anti-metastatic outcome of isoform-specific prolactin receptor targeting in breast cancerCancer Letters, 2015
- Efficient in Vivo Manipulation of Alternative Pre-mRNA Splicing Events Using Antisense Morpholinos in MiceJournal of Biological Chemistry, 2011
- Dystrophin Isoform Induction In Vivo by Antisense-mediated Alternative SplicingMolecular Therapy, 2010
- Short form 1b human prolactin receptor down-regulates expression of the long formJournal of Molecular Endocrinology, 2009
- A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophyRNA Biology, 2009
- Alternative isoform regulation in human tissue transcriptomesNature, 2008
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic MiceThe American Journal of Human Genetics, 2008
- A Splice Variant of CD99 Increases Motility and MMP-9 Expression of Human Breast Cancer Cells through the AKT-, ERK-, and JNK-dependent AP-1 Activation Signaling PathwaysJournal of Biological Chemistry, 2006
- S179D Prolactin Primarily Uses the Extrinsic Pathway and Mitogen-Activated Protein Kinase Signaling to Induce Apoptosis in Human Endothelial CellsEndocrinology, 2006
- S179D Prolactin Increases Vitamin D Receptor and p21 through Up-regulation of Short 1b Prolactin Receptor in Human Prostate Cancer CellsCancer Research, 2005